Effectiveness of azvudine against severe outcomes among hospitalized COVID-19 patients in Xinjiang, China: a single-center, retrospective, matched cohort study
A Kapar, S Xie, Z Guo, Y Nan, Y Du, X Yin… - Expert Review of Anti …, 2024 - Taylor & Francis
Background Since the end of 2022, Azvudine was widely used to treat hospitalized novel
coronavirus disease 2019 (COVID-19) patients in China. However, data on the clinical …
coronavirus disease 2019 (COVID-19) patients in China. However, data on the clinical …
Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation
Currently there is a lack of randomized trial data examining the use of the antiviral
nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2 infection. This target trial …
nirmatrelvir/ritonavir in paediatric patients with SARS-CoV-2 infection. This target trial …
A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral rebound
In a pivotal trial, a 5-day course of oral ritonavir-boosted nirmatrelvir decreased
hospitalization and death by 89.1% and reduced nasal viral load by 0.87 log relative to …
hospitalization and death by 89.1% and reduced nasal viral load by 0.87 log relative to …
[HTML][HTML] A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral …
S Esmaeili, K Owens, J Wagoner, SJ Polyak, JM White… - medRxiv, 2024 - ncbi.nlm.nih.gov
In a pivotal trial (EPIC-HR), a 5-day course of oral ritonavir-boosted nirmatrelvir, given early
during symptomatic SARS-CoV-2 infection (within three days of symptoms onset) …
during symptomatic SARS-CoV-2 infection (within three days of symptoms onset) …